Episurf Medical Q3: Slashing costs - Redeye

Redeye provides a more in-depth review of Episurf Medical’s Q3 report. On the back of announcements made during the quarter, we have made some downward adjustments to our sales estimates and now factor in a capital injection in H2 2025e. Our financial estimates revision and the inclusion of a capital injection renders a drastically lower fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1048581/episurf-medical-q3-slashing-costs?utm_source=finwire&utm_medium=RSS